Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
Moorman AV, Enshaei A, Murdy D, Joy M, Boer JM, den Boer ML, Pieters R, de Haas V, Horstmann MA, Escherich G, Johansson B, Marquart HV, Schmiegelow K, Hancock J, Moppett J, Heyman M. Moorman AV, et al. Among authors: schmiegelow k. Leukemia. 2024 Sep;38(9):2023-2026. doi: 10.1038/s41375-024-02329-0. Epub 2024 Jul 5. Leukemia. 2024. PMID: 38965371 Free PMC article. No abstract available.
Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92.
Calero Moreno TM, Gustafsson G, Garwicz S, Grandér D, Jonmundsson GK, Frost BM, Mäkipernaa A, Rasool O, Savolainen ER, Schmiegelow K, Söderhäll S, Vettenranta K, Wesenberg F, Einhorn S, Heyman M. Calero Moreno TM, et al. Among authors: schmiegelow k. Leukemia. 2002 Oct;16(10):2037-45. doi: 10.1038/sj.leu.2402697. Leukemia. 2002. PMID: 12357355
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia.
Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, Söderhäll S, Gustafsson MG, Lönnerholm G, Syvänen AC. Milani L, et al. Among authors: schmiegelow k. Blood. 2010 Feb 11;115(6):1214-25. doi: 10.1182/blood-2009-04-214668. Epub 2009 Nov 25. Blood. 2010. PMID: 19965625 Free article.
The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K, Heyman M, Gustafsson G, Lausen B, Wesenberg F, Kristinsson J, Vettenranta K, Schroeder H, Forestier E, Rosthoej S; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Leukemia. 2010 Apr;24(4):715-20. doi: 10.1038/leu.2009.303. Epub 2010 Feb 4. Leukemia. 2010. PMID: 20130603 Free article.
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: schmiegelow k. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
559 results